ESMO Congress 2026

The discussion here centers on sequential systemic therapy in advanced urothelial carcinoma (UC). First, the evidence base: none of the provided background literature concerns urothelial carcinoma, EV-Pembro, or published pivotal trial data for analogous regimens — ^[1][2][4][6] are neuroscience and behavioral studies, ^[3] is a randomized phase 2 neoadjuvant trial in triple-negative breast cancer, and ^[5] is animal-science work on urease inhibitors; none relates to GU oncology, so per the rules they are not cited as evidence. Accordingly, the exact figures of EV-Pembro's published studies are not disclosed in these materials, and the established efficacy benchmark for comparison remains to be confirmed.

The live posts indicate that the rapid oral GU session on Day 2 of ESMO26 began at 10:15am in Bilbao Auditorium - Hall 3. On content, Dr. Yohann Loriot delivered an overview on sequential systemic therapies in advanced UC, with the central question framed verbatim as “What comes after EV-Pembro?” Of the two posts, one reports only the session time and venue, while the other names the speaker and topic. The posts disclose no specific trial names, patient numbers, efficacy or safety figures, nor details such as the line of therapy, full drug name, or dosing of EV-Pembro in this context — all pending confirmation from official congress materials.

Based solely on what the live posts show, the advance here lies more in framing than in new numbers: with “what comes after EV-Pembro” set as the session's opening question, the discussion's center of gravity appears to be shifting from the choice of frontline combination to the sequencing of subsequent therapies. Loriot's presentation was an overview — the post itself calls it an excellent overview — rather than a readout update for a specific trial; and because the background materials contain no comparable published UC data, no numeric comparison with prior evidence is possible, so this step forward can only be described qualitatively.

The limitations are equally clear: this interpretation rests on just two live posts, which are agenda and atmosphere information with no slide figures, follow-up durations, or statistical results; “What comes after EV-Pembro” is an agenda-setting question, not an answer. Any conclusions should be re-verified once the official ESMO26 abstracts and full presentations are released.